請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32743
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林榮耀(Jung-Yaw Lin) | |
dc.contributor.author | Chia-Chu Tsai | en |
dc.contributor.author | 蔡家櫸 | zh_TW |
dc.date.accessioned | 2021-06-13T04:14:37Z | - |
dc.date.available | 2007-08-04 | |
dc.date.copyright | 2006-08-04 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-25 | |
dc.identifier.citation | Reference List
1. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200. 2. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-2604. 3. Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 2004;24:77-88. 4. Egner PA, Wang JB, Zhu YR, Zhang BC, Wu Y, Zhang QN, Qian GS, Kuang SY, Gange SJ, Jacobson LP, Helzlsouer KJ, Bailey GS, Groopman JD, Kensler TW. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci U S A 2001;98:14601-14606. 5. Wang LY, You SL, Lu SN, Ho HC, Wu MH, Sun CA, Yang HI, Chien-Jen C. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control 2003;14:241-250. 6. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-1213. 7. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-S83. 8. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-285. 9. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-354. 10. Wildi S, Pestalozzi BC, McCormack L, Clavien PA. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004;91:400-408. 11. Nishida N, Fukuda Y, Kokuryu H, Sadamoto T, Isowa G, Honda K, Yamaoka Y, Ikenaga M, Imura H, Ishizaki K. Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int J Cancer 1992;51:862-868. 12. Zhang LH, Qin LX, Ma ZC, Ye SL, Liu YK, Ye QH, Wu X, Huang W, Tang ZY. Allelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis. J Cancer Res Clin Oncol 2003;129:279-286. 13. Qin LX, Tang ZY, Ye SL, Liu YK, Ma ZC, Zhou XD, Wu ZQ, Lin ZY, Sun FX, Tian J, Guan XY, Pack SD, Zhuang ZP. Chromosome 8p deletion is associated with metastasis of human hepatocellular carcinoma when high and low metastatic models are compared. J Cancer Res Clin Oncol 2001;127:482-488. 14. Nishida N, Nishimura T, Ito T, Komeda T, Fukuda Y, Nakao K. Chromosomal instability and human hepatocarcinogenesis. Histol Histopathol 2003;18:897-909. 15. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, Van De RM, Botstein D, Brown PO. Gene expression patterns in human liver cancers. Mol Biol Cell 2002;13:1929-1939. 16. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-14868. 17. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61:2129-2137. 18. Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S, Goseki N, Matsubara O, Takenaka K, Shichita M, Tanaka K, Shuda M, Yamamoto M. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 1999;59:4990-4996. 19. Wu CG, Forgues M, Siddique S, Farnsworth J, Valerie K, Wang XW. SAGE transcript profiles of normal primary human hepatocytes expressing oncogenic hepatitis B virus X protein. FASEB J 2002;16:1665-1667. 20. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346. 21. Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology 2006;43:S145-S150. 22. Suzuki Y, Sugano S. Construction of full-length-enriched cDNA libraries. The oligo-capping method. Methods Mol Biol 2001;175:143-153. 23. Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 1997;200:149-156. 24. McGlynn KA, Edmonson MN, Michielli RA, London WT, Lin WY, Chen GC, Shen FM, Buetow KH. A phylogenetic analysis identifies heterogeneity among hepatocellular carcinomas. Hepatology 2002;36:1341-1348. 25. Desper R, Khan J, Schaffer AA. Tumor classification using phylogenetic methods on expression data. J Theor Biol 2004;228:477-496. 26. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006;24:259-267. 27. Coughlin PB. Antiplasmin: the forgotten serpin? FEBS J 2005;272:4852-4857. 28. Gho YS, Yoon WH, Chae CB. Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin. J Biol Chem 2002;277:9690-9694. 29. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 2001;21:146-170. 30. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003;S46-S58. 31. Olsson AK, Larsson H, Dixelius J, Johansson I, Lee C, Oellig C, Bjork I, Claesson-Welsh L. A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res 2004;64:599-605. 32. Szweras M, Liu D, Partridge EA, Pawling J, Sukhu B, Clokie C, Jahnen-Dechent W, Tenenbaum HC, Swallow CJ, Grynpas MD, Dennis JW. alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002;277:19991-19997. 33. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, Jen KL, Charron MJ, Jahnen-Dechent W, Grunberger G. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 2002;51:2450-2458. 34. Swallow CJ, Partridge EA, Macmillan JC, Tajirian T, DiGuglielmo GM, Hay K, Szweras M, Jahnen-Dechent W, Wrana JL, Redston M, Gallinger S, Dennis JW. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression. Cancer Res 2004;64:6402-6409. 35. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41-59. 36. Raidl M, Pirker C, Schulte-Hermann R, Aubele M, Kandioler-Eckersberger D, Wrba F, Micksche M, Berger W, Grasl-Kraupp B. Multiple chromosomal abnormalities in human liver (pre)neoplasia. J Hepatol 2004;40:660-668. 37. Knowles MA, Aveyard JS, Taylor CF, Harnden P, Bass S. Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett 2005;225:121-130. 38. Zhou X, Thorgeirsson SS, Popescu NC. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene 2004;23:1308-1313. 39. Jou YS, Lee CS, Chang YH, Hsiao CF, Chen CF, Chao CC, Wu LS, Yeh SH, Chen DS, Chen PJ. Clustering of minimal deleted regions reveals distinct genetic pathways of human hepatocellular carcinoma. Cancer Res 2004;64:3030-3036. 40. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-S50. 41. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis--A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000;32:970-979. 42. Laes J, Parada LA, Johansson B, Levan G, Szpirer C, Szpirer J. Alterations of P19ARF in rodent hepatoma cell lines but not in human primary liver cancer. Cancer Genet Cytogenet 2000;117:118-124. 43. Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 2002;36:692-701. 44. Hsu SJ, Nagase H, Balmain A. Identification of Fetuin-B as a member of a cystatin-like gene family on mouse chromosome 16 with tumor suppressor activity. Genome 2004;47:931-946. 45. Okochi O, Hibi K, Sakai M, Inoue S, Takeda S, Kaneko T, Nakao A. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 2003;9:5295-5298. 46. Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. Int J Cancer 2003;107:53-59. 47. Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 2005;18:412-420. 48. Roder K, Latasa MJ, Sul HS. Silencing of the mouse H-rev107 gene encoding a class II tumor suppressor by CpG methylation. J Biol Chem 2002;277:30543-30550. 49. Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, Schafer R. Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12. Oncogene 1998;17:1305-1312. 50. Roder K, Kim KH, Sul HS. Induction of murine H-rev107 gene expression by growth arrest and histone acetylation: involvement of an Sp1/Sp3-binding GC-box. Biochem Biophys Res Commun 2002;294:63-70. 51. Sers C, Husmann K, Nazarenko I, Reich S, Wiechen K, Zhumabayeva B, Adhikari P, Schroder K, Gontarewicz A, Schafer R. The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgamma-induced cell death in human ovarian carcinoma cells. Oncogene 2002;21:2829-2839. 52. Watari A, Yutsudo M. Multi-functional gene ASY/Nogo/RTN-X/RTN4: apoptosis, tumor suppression, and inhibition of neuronal regeneration. Apoptosis 2003;8:5-9. 53. Tagami S, Eguchi Y, Kinoshita M, Takeda M, Tsujimoto Y. A novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity. Oncogene 2000;19:5736-5746. 54. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005;24:287-291. 55. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005;24:267-276. 56. Dai W, Cogswell JP. Polo-like kinases and the microtubule organization center: targets for cancer therapies. Prog Cell Cycle Res 2003;5:327-334. 57. Gho YS, Yoon WH, Chae CB. Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin. J Biol Chem 2002;277:9690-9694. 58. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001;3:371-384. 59. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. 60. Niketeghad F, Decker HJ, Caselmann WH, Lund P, Geissler F, Dienes HP, Schirmacher P. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer 2001;85:697-704. 61. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA. Cell cycle control in breast cancer cells. J Cell Biochem 2005. 62. Liew CT, Li HM, Lo KW, Leow CK, Chan JY, Hin LY, Lau WY, Lai PB, Lim BK, Huang J, Leung WT, Wu S, Lee JC. High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 1999;18:789-795. 63. Tian Q, Taupin J, Elledge S, Robertson M, Anderson P. Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-1 during Fas-mediated apoptosis. J Exp Med 1995;182:865-874. 64. Oertle T, Schwab ME. Nogo and its paRTNers. Trends Cell Biol 2003;13:187-194. 65. Janke J, Schluter K, Jandrig B, Theile M, Kolble K, Arnold W, Grinstein E, Schwartz A, Estevez-Schwarz L, Schlag PM, Jockusch BM, Scherneck S. Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J Exp Med 2000;191:1675-1686. 66. Lee SH, Son MJ, Oh SH, Rho SB, Park K, Kim YJ, Park MS, Lee JH. Thymosin {beta}(10) inhibits angiogenesis and tumor growth by interfering with Ras function. Cancer Res 2005;65:137-148. 67. Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 2005;18:412-420. 68. Watabe K, Ito A, Koma YI, Kitamura Y. IGSF4: a new intercellular adhesion molecule that is called by three names, TSLC1, SgIGSF and SynCAM, by virtue of its diverse function. Histol Histopathol 2003;18:1321-1329. 69. Li W, Simarro M, Kedersha N, Anderson P. FAST is a survival protein that senses mitochondrial stress and modulates TIA-1-regulated changes in protein expression. Mol Cell Biol 2004;24:10718-10732. 70. Pinte S, Stankovic-Valentin N, Deltour S, Rood BR, Guerardel C, Leprince D. The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties. J Biol Chem 2004;279:38313-38324. 71. Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, Pietrzynski G, Stanimirovic D, Alakhov V. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J Biol Chem 2005;280:20833-20841. 72. Banerjee AG, Liu J, Yuan Y, Gopalakrishnan VK, Johansson SL, Dinda AK, Gupta NP, Trevino L, Vishwanatha JK. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA. Mol Cancer 2003;2:34. 73. Felez J, Chanquia CJ, Fabregas P, Plow EF, Miles LA. Competition between plasminogen and tissue plasminogen activator for cellular binding sites. Blood 1993;82:2433-2441. 74. Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, Cai T, Zhang X, Xiao HS, Qu J, Liu F, Huang QH, Cheng ZH, Li NG, Du JJ, Hu W, Shen KT, Lu G, Fu G, Zhong M, Xu SH, Gu WY, Huang W, Zhao XT, Hu GX, Gu JR, Chen Z, Han ZG. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci U S A 2001;98:15089-15094. 75. Sers C, Emmenegger U, Husmann K, Bucher K, Andres AC, Schafer R. Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. J Cell Biol 1997;136:935-944. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32743 | - |
dc.description.abstract | 肝癌是台灣發生率及死亡率最高的癌症之ㄧ,B型肝炎或C型肝炎的感染、黃趜毒素及酒精的攝取已經被證明直接與肝癌的發生有關。在致癌過程中,累積染色體及基因的變異會使得正常肝細胞轉型並逐漸惡化成為肝癌細胞,其中基因突變及基因表現量的改變在致肝癌機制中扮演了重要的角色。我們與日本東京大學菅野純一及鈴木驤博士合作建構肝癌及其周邊組織之全長cDNA資料庫,並利用高速自動化設備,完成了58,251個肝癌及其周邊正常組織之cDNA定序,並經過電腦進行基因比對,我們找到180個在肝癌中表現量上升及279個在肝癌中表現量下降的基因。根據其細胞功能作進一步的分類後,發現許多可能與肝癌的發生以及發展有密切的關係,這些基因及其表現量變化與其影響肝細胞之生理功能,包括:1,致癌基因;2,細胞凋亡;3,抑癌基因;4,訊息傳遞;5,細胞週期;6,血管新生等類型之基因。
我們並利用即時定量PCR技術,在45對肝癌組織中定量分析165個基因的表現改變,其中102個基因有顯著的變化,其中又有26個基因被鑑定為與肝癌末期發展有關,我們利用phylogenetic的方法分析其中與早期及末期相關的61個基因,有八個基因群組被發現,其中第五到第八組又與肝癌末期關係較大,以此可以證明這些基因在肝癌進展中扮演非常重要的角色。此外,為了瞭解基因與病患死亡率的相關性,我們也利用Kaplan-Meier圖表進行分析,發現了14個基因與死亡可能有關而其中有10個基因亦與肝癌末期相關,這些良好的關聯性更證明我們可以利用這些方法,成功的鑑定出許多與肝癌進展有關的基因,希望藉此可以闡明這些基因與肝癌之發展,以開發肝癌之診斷方法及治療藥物。 | zh_TW |
dc.description.abstract | HCC (Hepatocellular carcinoma) is one of the most frequent cancers with high mortality rate in Taiwan and worldwide. During hepatocarcinogenesis, accumulation of chromosomal alternations and genetic mutations may cause the transformation of normal liver cells into malignant HCC cells, and gene expression changes are also playing important roles in this process. In order to identify the HCC-related genes, we cooperated with Drs. S. Sugano and Y. Suzuki in University of Tokyo and constructed the full-length cDNA library of HCC and its adjacent normal tissues. By using high-throughput DNA sequencer, 58,251 cDNA clones of HCC and its adjacent normal liver tissues were sequenced, and genes were identified by comparison with GeneBank (NCBI). Among them, 180 up-regulated and 279 down-regulated genes were found in HCC. From these genes, 165 genes were subjected to real-time quantitative PCR analysis (Q-PCR) in 45 pairs of HCC and their surrounding normal liver tissues, which may be correlated with hepatocarcinogenesis and tumor progression, and 102 genes with more than two-fold differential expression were identified, which were related to oncogenes, apoptosis, tumor suppressor gene, signal transduction, cell cycle, and angiogenesis. With clinicopathological data and statistical analysis, we revealed 26 genes to be strongly associated with advanced HCC, including VEGF, MMP9, RB1, etc. In addition, 61 genes with high differential expression and related to tumorigenesis were subjected to phylogenetic analysis, and with eight gene clusters were obtained related to tumor development. Among them, oncogenic and cell cycle genes were greatly contributed to early events of HCC development while genes involved in angiogenesis and antiapoptotisis were associated with late development. We also identified 14 genes significantly associated with patient survival. By pathway analysis, present study provides 3 molecular networks of HCC-associated genes, in which N-RAS, RAF, VEGF, and KNG were played central role in the network 1. These genes could be good candidates for the development of therapeutic and diagnostic targets. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T04:14:37Z (GMT). No. of bitstreams: 1 ntu-95-F87442021-1.pdf: 2318361 bytes, checksum: 16bf5bfaba22932e504c9bc9b4bd226a (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | Key words 8
Abbreviations used 9 Instruments 11 中文摘要: 12 Abstract: 14 Overview and Rational: 16 Introduction: 17 Materials and Methods: 21 1. HCC patients and tissue samples 21 2. Total RNA and mRNA isolation 21 3. Construction of full-length cDNA library by oligo-capping method 23 4. Real-time quantitative PCR 30 5. Statistic analysis and Treeview plotting 31 6. Kaplan Meier analysis 32 7. Phylogenetic analysis 32 8. Genetic network analysis 33 Results: 34 1. Construction of full-length cDNA library of HCC and the surrounding non-cancerous tissues 34 2. General information of full-length cDNA library 34 3. Identification of differentially expressed genes in HCC 35 4. Changes of cellular functions during hepatocarcinogenesis 36 5. Chromosomal distribution of highly differentially expressed genes 37 6. Gene expression profiles by real-time quantitative PCR (Q-PCR) in 45 HCC tissue pairs 38 7. Functional classification of 102 deregulated genes 40 8. Identification of marker genes associated with stage of tumor progression 41 9. Genes associated with patient’s survival 42 10. Phylogenetic analysis of gene expression profiles 43 11. Chromosomal location of differentially expressed genes 44 12. Biological network analysis 45 Discussion 46 1. Loss of liver functions by dedifferentiation of HCC cells 46 2. Underexpressed TSG found in most of HCC tissues 48 3. Uncontrolled growth signaling by overexpressed oncogenes 49 4. Dysregulation of cell cycle progression 50 5. Angiogenesis induced by HCC 50 6. Phylogenic classification of stage-related genes 51 7. Chromosomal alternation contributing to gene expression change 53 8. Identification of new HCC-associated genes 54 9. From patterns to pathways 57 10. Conclusion 58 Legends 60 Figures 65 Tables 79 References 91 Supplementary data 99 | |
dc.language.iso | en | |
dc.title | 利用全長cDNA資料庫鑑定與肝癌相關之目標基因 | zh_TW |
dc.title | Identification of Hepatocellular Carcinoma Associated Candidate Genes by Analysis of Full-length cDNA Library | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 張明富(Ming-Fu Chang),包家駒(Chia-Chu Pao),李伯皇(Po-Huang Li),嚴仲陽(Jeffrey J. Y. Yen),鐘邦柱(Bon-Chu Chung),魏耀輝(Yau-Huei Wei) | |
dc.subject.keyword | 肝癌,全長cDNA資料庫,致癌基因,抑癌基因, | zh_TW |
dc.subject.keyword | Hepatocellular carcinoma,Full-length cDNA library,Oncogene,tumor suppressor gene, | en |
dc.relation.page | 115 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-25 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 2.26 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。